Pedro Torres-Saavedra

5PUBLICATIONS
76CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Stochastic analysis and modellingPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jun 25, 2026
Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma.

|Mar 06, 2026
The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial.

Joanne B Weidhaas, Jonathan Harris, Maura L Gillison

|Jan 03, 2026
A note on rank-preserving structural failure time models to account for crossover.

Pedro A Torres-Saavedra, Boris Freidlin, Jong-Hyeon Jeong

|Jan 22, 2025
Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer.

Mitchell Machtay, Pedro A Torres-Saavedra, Wade Thorstad

|Dec 10, 2024
Association between Locoregional Failure and NFE2L2/KEAP1/CUL3 Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer.

Li Guan, Pedro A Torres-Saavedra, Xiaobei Zhao

Pageof 1

Frequent Collaborators

4 joint publications

Quynh-Thu Le

3 joint publications

Sue S Yom

3 joint publications

Jonathan Harris

2 joint publications

D Neil Hayes